AR-induced ZEB1-AS1 represents poor prognosis in cholangiocarcinoma and facilitates tumor stemness, proliferation and invasion through mediating miR-133b/HOXB8.
Bile Duct Neoplasms
/ etiology
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
Cell Survival
/ genetics
Cell Transformation, Neoplastic
/ genetics
Cholangiocarcinoma
/ etiology
Epithelial-Mesenchymal Transition
/ genetics
Gene Expression Regulation, Neoplastic
Homeodomain Proteins
/ genetics
Humans
MicroRNAs
/ genetics
Neoplasm Metastasis
Neoplasm Staging
Neoplastic Stem Cells
/ metabolism
Prognosis
RNA Interference
RNA, Long Noncoding
/ genetics
ROC Curve
Receptors, Androgen
/ metabolism
Signal Transduction
HOXB8
ZEB1-AS1
cholangiocarcinoma
miR-133b
prognosis
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
24 01 2020
24 01 2020
Historique:
received:
04
10
2019
accepted:
25
12
2019
pubmed:
25
1
2020
medline:
12
1
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) has displayed vital regulatory function in various tumors. However, the biological function of ZEB1-AS1 in cholangiocarcinoma (CCA) remains unclear. In this study, we confirmed that ZEB1-AS1 expression was increased in CCA tissues and cells, respectively. Upregulated ZEB1-AS1 was related to lymph node invasion, advanced TNM stage and poor survival of CCA patients. ZEB1-AS1 exhibited high sensitivity and specificity to be an independent poor prognostic factor of patients with CCA. Functionally, knocking down ZEB1-AS1 attenuated tumor cell stemness, restrained cellular viability
Identifiants
pubmed: 31978895
doi: 10.18632/aging.102680
pii: 102680
pmc: PMC7053610
doi:
Substances chimiques
AR protein, human
0
HOXB8 protein, human
0
Homeodomain Proteins
0
MIRN133 microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
Receptors, Androgen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1237-1255Références
Oncogene. 2016 Mar 24;35(12):1575-84
pubmed: 26073087
Eur J Pharmacol. 2019 Jul 5;854:22-27
pubmed: 30954562
Aging (Albany NY). 2019 Sep 3;11(17):6930-6940
pubmed: 31479417
Gynecol Oncol. 2013 May;129(2):358-63
pubmed: 23438671
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
Am J Pathol. 2016 May;186(5):1092-102
pubmed: 26945106
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Aging (Albany NY). 2019 Aug 20;11(16):6237-6251
pubmed: 31433789
Cell Prolif. 2018 Feb;51(1):
pubmed: 29226522
Aging (Albany NY). 2019 Jan 19;11(2):467-479
pubmed: 30659574
J Cell Physiol. 2019 Aug;234(10):17113-17126
pubmed: 30888066
Cancer Lett. 2015 Dec 1;369(1):58-66
pubmed: 26276722
Cancer Cell Int. 2019 Jan 3;19:3
pubmed: 30622439
Br J Cancer. 2014 Sep 23;111(7):1275-84
pubmed: 25032731
Mol Cancer. 2013 Dec 13;12:164
pubmed: 24330809
J Cancer Res Clin Oncol. 2017 Mar;143(3):385-397
pubmed: 27761656
Gene. 2018 Mar 1;645:131-136
pubmed: 29246536
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Prostate. 2018 Dec;78(16):1248-1261
pubmed: 30105831
Am J Transl Res. 2018 Feb 15;10(2):605-617
pubmed: 29511455
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11871-6
pubmed: 26617942
Cell Death Dis. 2018 Jul 3;9(7):746
pubmed: 29970899
Cancer Genet. 2017 Oct;216-217:105-110
pubmed: 29025584
Annu Rev Physiol. 2013;75:201-24
pubmed: 23157556
Surg Oncol. 2017 Dec;26(4):527-534
pubmed: 29113674
Cell Death Dis. 2019 Feb 12;10(2):129
pubmed: 30755599
Aging (Albany NY). 2018 Aug 17;10(8):2037-2050
pubmed: 30125263
Cell. 2018 Jul 12;174(2):350-362.e17
pubmed: 29887379
Aging (Albany NY). 2019 May 6;11(9):2610-2627
pubmed: 31061236